Ursolic acid, a constituent from Rosmarinus officinalis, is a triterpenoid compound which has been extensively known for its anticancer and antioxidant properties. In the present study, we investigated the antidepressant-like effect of ursolic acid isolated from this plant in two predictive tests of antidepressant property, the tail suspension test (TST) and the forced swimming test (FST) in mice. Furthermore, the involvement of dopaminergic system in its antidepressant-like effect was investigated in the TST. Ursolic acid reduced the immobility time in the TST (0.01 and 0.1 mg/kg, p.o.) and in the FST (10 mg/kg, p.o.), similar to fluoxetine (10 mg/kg, p.o.), imipramine (1 mg/kg, p.o.) and bupropion (10 mg/kg, p.o.). The effect of ursolic acid (0.1 mg/kg, p.o.) in the TST was prevented by the pretreatment of mice with SCH23390 (0.05 mg/kg, s.c., a dopamine D 1 receptor antagonist) and sulpiride (50 mg/kg, i.p., a dopamine D 2 receptor antagonist). The administration of a sub-effective dose of ursolic acid (0.001 mg/kg, p.o.) in combination with sub-effective doses of SKF38393 (0.1 mg/kg, s.c., a dopamine D 1 receptor agonist), apomorphine (0.5 μg/kg, i.p., a preferential dopamine D 2 receptor agonist) or bupropion (1 mg/kg, i.p., a dual dopamine/ noradrenaline reuptake inhibitor) reduced the immobility time in the TST as compared with either drug alone. Ursolic acid and dopaminergic agents alone or in combination did not cause significant alterations in the locomotor and exploratory activities. These results indicate that the antidepressant-like effect of ursolic acid in the TST is likely mediated by an interaction with the dopaminergic system, through the activation of dopamine D 1 and D 2 receptors.
Introduction
Depression is projected to become the second biggest contributor to the global burden of disease and disability by the year 2020 (Pitchot et al., 2010) . It is a heterogeneous disorder often manifested with symptoms at the psychological, behavioral and physiological levels. Noteworthy, there are high rates of comorbidity of psychiatric and neurodegenerative disorders, type 2 diabetes mellitus, cancer, cardiovascular disease and depression (Evans et al., 2005; Krishnan and Nestler, 2008) .
The treatment of depression with conventional antidepressants (i.e., monoamine oxidase inhibitors, tricyclics, selective serotonin reuptake inhibitors and selective noradrenaline reuptake inhibitors) has several drawbacks. The heterogeneity of clinical response to antidepressant and susceptibility to adverse effects are major clinical problems and support the research for new therapeutic agents to treat depression (Brunello et al., 2002; MacGillivray et al., 2003; Wong and Licinio, 2001) . Herbal therapies may be effective alternatives in the treatment of depression, as include the case of St John's wort (Akhondzadeh and Maleki, 2006; Bilia et al., 2002; Whiskey et al., 2001 ) and the search for novel pharmacotherapy from medicinal plants and compounds isolated from plant extracts for this psychiatric disorder has progressed significantly (Zhang, 2004) .
Aiming at searching new antidepressant agents, our group has studied the antidepressant potential of some plant extracts (Freitas et al., 2010; Machado et al., 2007 Machado et al., , 2009 Rodrigues et al., 2002) and bioactive compounds (Capra et al., 2010; Machado et al., 2008) . We have recently demonstrated that the extract of Rosmarinus officinalis produces an antidepressant-like effect in the mouse tail suspension test (TST) and in the forced swimming test (FST), by a mechanism dependent on the interaction with the monoaminergic systems (Machado et al., 2009) . One of the main constituents present in R. officinalis is ursolic acid (3β-hydroxy-urs-12-en-28-oic acid), a pentacyclic triterpenoid compound, that has a broad range of biological effects, such as antioxidant (Tsai and Yin, 2008) , anti-inflammatory (Baricevic et al., 2001; Benincá et al., 2011 ), anti-tumoral (Yan-xia et al., 2010 , anti-diabetic (Jang et al., 2009 ) and neuroprotective (Lu et al., 2007; Shih et al., 2004) . Noteworthy, ursolic acid was shown to be able to protect PC12 cells against the dopaminergic neurotoxin MPP + (Tsai and Yin, 2008) .
Several studies have indicated that the dopaminergic system plays a significant role in the pathophysiology of depression and on the mechanisms of action of some current prescribed antidepressant agents, mainly bupropion (D'Aquila et al., 2000; Dunlop and Nemeroff, 2007; Papakostas, 2006) . The investigation of novel antidepressant agents that act on this system is justified to improve outcomes for patients with treatment-resistant and non remitting depression (Dunlop and Nemeroff, 2007) . Therefore, this study aims, firstly, to examine the antidepressant-like action of ursolic acid isolated from R. officinalis in the mouse TST and FST, and secondly, to investigate by the use of pharmacological procedures the possible participation of the dopaminergic system in its antidepressant-like action.
Methods

Isolation of ursolic acid from R officinalis
Stems and leaves of R. officinalis (Labiatae) were collected in Santo Amaro da Imperatriz, Santa Catarina, and identified by Dr. Daniel Falkenberg, from the Department of Botany, Federal University of Santa Catarina. A voucher specimen (Excicata number 34918) was deposited in the Herbarium of the Department of Botany, Federal University of Santa Catarina, Santa Catarina, Brazil. The procedure to obtain the crude extract from R. officinalis was described previously (Machado et al., 2009 ). The crude extract was subjected to passage on a short silica gel 60 (Vetec -63-230 mesh) column with hexane, ethyl acetate and ethanol in order of polarity, to give three fractions: the hexane (HEX), ethyl acetate (AcOEt) and ethanolic (EtOH). Part of the AcOEt fraction (8.83 g) was submitted to the silica gel column eluted with hexane-ethyl acetate gradient in increasing polarity, to give 33 fractions. Fractions 20-33 eluted with hexane-acetone solution (8:2 v/v) were met and purified by flash chromatography (silica gel 60 column; Vetec-230-400 mesh) with isocratic elution (Hexane: Acetone 4:1 v/v) to give ursolic acid (87 mg). Ursolic acid was identified by analysis of IR and NMR data and comparison with literature (Mahato and Kundu, 1994) .
Animals
Male Swiss mice (40-50 g, 60-70 days old) were maintained at constant room temperature (21 ± 1°C) with free access to water and food, under a 12:12 h light:dark cycle (lights on at 07:00 h). Mice were allowed to acclimatize to the holding room for 24 h before the behavioral procedure. The animals were randomly distributed into specified experimental groups. All experiments were carried out between 11:00 and 17:00 h, with each animal used only once (N= 7-10 animals per group). All procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of the Institution. All efforts were made to minimize animals suffering and to reduce the number of animals used in the experiments.
Drugs and treatment
The following drugs were used: (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390), sulpiride, apomorphine, 1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SKF38393), fluoxetine, imipramine and bupropion, all from Sigma Chemical Company, St. Louis, MO, U.S.A. All drugs were administered by intraperitoneal (i.p.) route, except SCH23390 and SKF38393 that were administered by subcutaneous (s.c.) route. All drugs were administered in a constant volume of 10 ml/kg body weight. Drugs were dissolved in saline, except bupropion that were diluted in distilled water and sulpiride that was diluted in saline with 5% dimethylsulfoxide (DMSO). Control animals received appropriate vehicle.
Ursolic acid (0.001-10 mg/kg) was dissolved in distilled water with 10% Tween 80 and administered acutely by oral route (p.o.). The solution of ursolic acid was freshly done from the lyophilized power immediately before its administration by gavage. A control group received distilled water with 10% Tween 80 as vehicle.
Experimental design
In order to investigate the antidepressant-like effect produced by an oral administration of ursolic acid, it was administered at the dose range 0.001-10 mg/kg (p.o.), 60 min before the TST, FST or open-field test. The clinically used antidepressants fluoxetine (10 mg/kg, p.o.), imipramine (1 mg/kg, p.o.) and bupropion (10 mg/kg, p.o.) were also administered to independent group of mice 60 min before the TST. Moreover, bupropion (10 mg/kg, p.o.) was also administered 60 min before the FST.
In order to investigate the involvement of the dopaminergic system in the antidepressant-like action of ursolic acid in the TST, the following experimental protocols were performed:
Firstly, mice were pretreated with vehicle (control group), SCH23390 (0.05 mg/kg, s.c., a dopamine D 1 receptor antagonist) or sulpiride (50 mg/kg, i.p., a dopamine D 2 receptor antagonist) (Capra et al., 2010; Machado et al., 2007) and 30 min later they received vehicle or ursolic acid (0.1 mg/kg, p.o.). A further 60 min was allowed to elapse before the animals were tested in the TST or open-field test. In order to minimize the number of mice used in the experiments this protocol was carried out in the same day (same vehicle+vehicle and vehicle+ursolic acid groups).
In a second experimental approach, we studied the possible synergistic antidepressant-like effect elicited by the administration of a sub-effective dose of ursolic acid (0.001 mg/kg, p.o.) with sub-effective doses of SKF38393 (0.1 mg/kg, s.c., a dopamine D 1 receptor agonist) or apomorphine (0.5 μg/kg, i.p., a preferential dopamine D 2 receptor agonist) Cunha et al., in press) . Ursolic acid or vehicle were administered 30 min before the administration of the dopamine receptor agonists. In another set of experiments, a sub-effective dose of ursolic acid (0.001 mg/kg, p.o.) was administered immediately before the administration of a sub-effective dose of bupropion (1 mg/kg, p.o., a dopamine/ noradrenaline reuptake inhibitor) (Cooper et al., 1994; Mortensen and Amara, 2006; Richelson, 2003) . A further 60 min was allowed to elapse before the animals were tested in the TST or open-field test. In order to minimize the number of mice used in the experiments this protocol was carried out in the same day (same vehicle + vehicle and vehicle + ursolic acid groups).
All the experimental protocols and drug doses utilized in the present study were based on previous studies from our group and literature (Binfaré et al., 2009 Capra et al., 2010; Cooper et al., 1994; Cunha et al., 2008, in press; Machado et al., 2007 Machado et al., , 2009 Mortensen and Amara, 2006; Richelson, 2003; Rodrigues et al., 2002) . These protocols are largely standardized in our laboratory as shown in the study of the mechanism of action of various compounds with antidepressant action.
Behavioral tests
Tail suspension test (TST)
The TST has become one of the most widely used tests for assessing antidepressant-like activity in mice. It is based on the fact that animals subjected to the short-term inescapable stress of being suspended by their tail, will develop an immobile posture. The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. (1985) . Briefly, mice both acoustically and visually isolated were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was recorded during a 6 min period. Mice were considered immobile only when they hung passively and completely motionless. Antidepressant treatments reduce the time of immobility and increase active escape behaviors displayed during inescapable situation in the TST (Cryan et al., 2005; Machado et al., 2007 Machado et al., , 2009 ). The immobility time was recorded by an observer blind to the drug treatment.
Forced swimming test (FST)
The FST was carried out in mice individually forced to swim in an open cylindrical container (diameter 10 cm, height 25 cm), containing 19 cm of water at 25± 1°C; the total duration of immobility during the 6-min test was scored as described previously (Kaster et al., 2005; Machado et al., 2007 Machado et al., , 2009 . Each mouse was judged to be immobile when it ceased struggling and remained floating motion-less in the water, making only those movements necessary to keep its head above water. A decrease in the duration of immobility is indicative of an antidepressant-like effect (Porsolt et al., 1977) .
Open-field test
To assess the possible effects of ursolic acid and the other drugs used in the present study on locomotor and exploratory activities, an independent group of mice was evaluated in the open-field paradigm as previously described (Machado et al., 2007; Rodrigues et al., 1996) . Mice were individually placed in a wooden box (40 × 60 × 50 cm) with the floor divided into 12 equal rectangles. The number of crossings defined as the rectangles crossed by the animal with its four paws and the number of rearings defined as the animal standing upright on its hind legs were registered during a period of 6 min. The number of crossings was considered as indicative of locomotor activity and number of rearings was an indicative of exploratory behavior (Felipe et al., 2007; Rodrigues et al., 1996) . Crossings and rearings were recorded by an observer blind to the drug treatment. The floor of the open-field apparatus was cleaned with 10% ethanol between tests to remove any olfactory cues.
Statistical analysis
Comparisons between experimental and control groups were performed by analysis of variance (ANOVA) followed by Tukey HSD test when appropriate. A value of P b 0.05 was considered to be significant.
Results
Effects of acute treatment with ursolic acid on the immobility time in the TST and FST and on the locomotor and exploratory activities in the open-field test
The effects of the oral administration of ursolic acid on the immobility time in the TST and FST are shown in Fig. 1 . Ursolic acid given by oral route decreased the immobility time in the TST (at the dose of 0.01 and 0.1 mg/kg, Fig. 1A ) and FST (10 mg/kg, Fig. 1E ) as compared to the control group. The percent of reduction in the immobility time was 19.4%, 27.1% in the TST and 13.5% in the FST, respectively. Additionally, Fig. 1 shows that fluoxetine (a selective serotonin reuptake inhibitor -SSRI, Fig. 1B ), imipramine (a tricyclic antidepressant, Fig. 1C ) and bupropion (a dual dopamine/noradrenaline reuptake inhibitor, Fig. 1D ), administered at the doses of 10, 1 and 10 mg/kg, p.o., respectively, were effective in the TST (reduction of 28.5%, 28.8% and 21.6% in the immobility time, respectively). The one-way ANOVA revealed a significant effect of treatment of fluoxetine [F(1,14)= 22.82; Pb 0.01], imipramine [F(1,15)= 56.57; P b 0.01] and bupropion treatment [F(1,16) = 9.14; Pb 0.01].
Investigation of the dopaminergic mechanisms underlying the antidepressant-like effect of ursolic acid in the TST
The results shown in Fig. 2A indicate that the pretreatment of mice with SCH23390 (0.05 mg/kg, s.c.) prevented the antidepressant-like effect elicited by ursolic acid (0.1 mg/kg, p.o.) in the TST. This effect was observed when compared the SCH23390+ ursolic acid group with the antidepressant-like effect of ursolic acid showed in the vehicle + ursolic acid group. A two-way ANOVA revealed significant differences for Similarly, Table 3 shows that ursolic acid (0.001 mg/kg, p.o.) alone or in combination with apomorphine (0.5 μg/kg, i.p.) caused no significant effects on the number of crossings and rearings in the 
Discussion
This study shows, to our knowledge for the first time, that the acute administration of ursolic acid by p.o. route is effective to produce a significant antidepressant-like response in both TST and FST in mice. Noteworthy, ursolic acid caused a reduction in the immobility time at a lower dose in the TST (0.01 and 0.1 mg/kg, p.o.) as compared to the FST (10 mg/kg, p.o.). Interestingly, the U-shaped dose-response curve of ursolic acid in the TST is similar to the dose-response curve of other compounds isolated from plants, such as berberine, rutin, nobiletin, isoliquiritin in the FST and in the TST Peng et al., 2007; Yi et al., 2011; Wang et al., 2008) and ascorbic acid in the TST (Binfaré et al., 2009) . Moreover, the antidepressant-like effect of ursolic acid was similar to the effect produced by the classical antidepressants fluoxetine, imipramine and bupropion in the TST and bupropion in the FST.
The TST and FST are reported to be predictive tests of antidepressant action sensitive to the acute administration of antidepressant drugs ( Cryan et al., 2005; Porsolt et al., 1977; Steru et al., 1985) . These behavioral tests induce a state of immobility in animals facing an inescapable situation and the antidepressant-like activity of a compound is expressed by a decrease in the immobility duration (Bourin et al., 2005; Porsolt et al., 1977; Steru et al., 1985) . It is important to note that the TST was more sensitive to the effects of ursolic acid than the FST, since this compound caused an antidepressant response at lower doses than in the FST. In line with this result, Cryan et al. (2005) reported that the TST was proposed to have a greater pharmacological sensitivity as compared with the FST. Indeed, several evidence demonstrate that both tests rely on different neurochemical substrates to mediate their behavioral effects (Bai et al., 2001; Cryan et al., 2005; Mombereau et al., 2004 ). However, it should be considered that drugs enhancing the locomotor activity may give a false positive effect in this test. Thus, in order to rule out the possibility that the reduction in the immobility time elicited by a drug is due to an enhancement in the locomotor activity, behavioral tests assessing the locomotor activity of mice, such as the open-field test, are usually employed. In this study, we observed that the reduction in the immobility time elicited by ursolic acid in TST is not due to a psychostimulant action, since the doses (0.01 and 0.1 mg/kg) of this compound, that were able to induce a significant decrease in the immobility time in the TST did not increase the locomotor activity in the open-field. Indeed, a tendency to decrease the number of crossings and rearings in this test was observed, which may underestimate the antidepressant-like effect of ursolic acid.
Ursolic acid is one of the main constituents of R. officinalis (Benincá et al., 2011) . It is interesting to note that the extract from this plant exerts antidepressant-like effect in the TST at the dose range of 10-100 mg/kg, p.o. (Machado et al., 2009) . Therefore, the results presented here indicate that ursolic acid has greater potency (but similar efficacy) as compared to the extract from R. officinalis in the TST, since it produces antidepressant-like effect at a dose 100-10,000 fold lower than the active doses of the extract from R. officinalis. These results indicate that ursolic acid exerts a significant role in the antidepressant-like effect of the extract of this plant in the TST.
A protective role for ursolic acid against the cell death induced by the dopaminergic neurotoxin MPP + in PC12 cells (Tsai and Yin, 2008 ) through anti-oxidative and anti-inflammatory mechanisms was recently reported. Moreover, a recent study reported that ursolic acid was able to protect haloperidol-induced catalepsy in mice (Pemminati et al., 2011) . These results suggest that this compound might modulate the dopaminergic system. Of note, this system has been implicated in pathophysiology of depression and in the mechanism of action of some antidepressant agents (Dailly et al., 2004; Dunlop and Nemeroff, 2007; Papakostas, 2006; Yamada et al., 2004) . Several clinical studies, including postmortem investigations, have shown that depression may be related to reduced dopamine levels and its metabolite homovanillic acid in the brain in depressed and/or suicidal patients compared to normal individuals, indicating a diminished dopamine turnover (Dunlop and Nemeroff, 2007; Ebmeier et al., 2006; Papakostas, 2006) . Since dopamine is the main neurotransmitter involved in the mesocorticolimbic reward pathway, it has been proposed that an increase in dopaminergic neurotransmission might counteract the anhedonia, which is a core symptom of depression (D'Aquila et al., 2000) . Moreover, some substances that modulate the dopaminergic system, such as bupropion, are clinically used as antidepressants (Dhillon et al., 2008) . Animal models predictive of antidepressant action, such as the TST show considerable responsiveness to manipulations of dopaminergic neurotransmission (Dunlop and Nemeroff, 2007) . Previous studies of our group literature data have shown that conventional and putative antidepressant agents (Binfaré et al., 2009 Cunha et al., 2008; Hirano et al., 2007) as well as plant extracts and their bioactive compounds whose mechanisms of action are mediated, at least in part, by the modulation of the dopaminergic system produce positive results in the TST (Capra et al., 2010; Freitas et al., 2010; Machado et al., 2007 Machado et al., , 2009 Yi et al., 2011) .
The results presented here clearly indicate that the dopaminergic system is implicated in the antidepressant-like action of ursolic acid in the TST. This conclusion derives from some set of evidence. First, the reversal of the antidepressant-like effect of ursolic acid by SCH23390 or sulpiride, selective dopamine D 1 and D 2 receptor antagonists, respectively, is an indicative that the effect of ursolic acid in the TST is dependent on the activation of these receptors. This result is somewhat in agreement with previous studies that show that SCH23390 and sulpiride are able to prevent the antidepressant-like effect of bupropion in the forced swimming test (Yamada et al., 2004) and several putative antidepressant agents in the TST Capra et al., 2010; Hirano et al., 2007; Machado et al., 2009; Yi et al., 2011) . The second evidence is given by the finding that the administration of a sub-effective dose of ursolic acid with SKF38393 (dopamine D 1 receptor agonist) or apomorphine (a preferential dopamine D 2 receptor agonist) produced a reduction in the immobility time, as compared with the administration of either drug alone, suggesting a synergistic effect of ursolic acid with these agonists in the TST. Moreover, a recent study reported that the pre-treatment of mice with the dopamine D 2 receptor antagonist sulpiride (50 mg/kg, i.p.) prevented the antidepressant-like action of apomorphine (50 μg/kg, i.p.) in the TST, indicating the involvement of dopamine D 2 receptors in the mechanism of action of apormorphine (Cunha et al., in press) . Consistent with this finding, a study demonstrated that apomorphine activates preferentially dopamine D 2 receptors (16.0% more preference for D 2 receptors than for D 1 receptors) (Millan et al., 2002) . These results further reinforce the notion that the antidepressant-like effect of ursolic acid in this test is dependent on an activation of dopamine D 1 and D 2 receptors.
The antidepressant bupropion is a dual dopamine/noradrenaline reuptake inhibitor clinically used by its ability to inhibit the uptake of dopamine somewhat more selectively than it inhibits uptake of noradrenaline or serotonin, although it has been shown that its effects are at least partially mediated by a noradrenergic mechanism (Cooper et al., 1994; Richelson, 2003; Sanchez and Hyttel, 1999) . Previous studies showed a synergistic effect of antidepressant compounds such as zinc, creatine and ascorbic acid with bupropion, administered at sub-effective doses in the TST Cunha et al., 2008, in press ). Similar to these results, our study showed the synergistic antidepressant-like effect of ursolic acid with bupropion. Interestingly, to our knowledge it is the first evidence that ursolic acid is able to produce a synergistic antidepressant-effect with buproprion.
However, it is important to emphasize that the current results do not allow us to indicate whether ursolic acid directly interact with dopamine D 1 and D 2 receptors or whether it enhance dopamine levels in the synaptic cleft that in turn activates these receptors. Alternatively, we can hypothesize that ursolic acid may enhance serotonergic transmission that could, in turn, cause a dopaminergic activation. In line with this hypothesis, several studies have suggested that SSRIs acting on the serotonergic system may indirectly affect dopaminergic Results are expressed as mean ± S.E.M.
neurotransmission by increasing the extracellular levels of dopamine (Clark et al., 1996; Gobert et al., 1997; Rogóz and Gołembiowska, 2010) , an action that may play a role in antidepressant-like effects of these antidepressants. Additionally, the acute effects of several SSRIs (Renard et al., 2001) in the FST were reversed by dopamine D 1 and D 2 antagonists and the dopamine D 1 agonist SKF38393 enhances the anti-immobility effects of SSRIs, including fluoxetine, citalopram, paroxetine and fluvoxamine (Renard et al., 2001) . Moreover, it has been reported that the treatment with SCH23390 and sulpiride significantly inhibited the effect of imipramine in the FST and TST (Mancinelli et al., 1991; D'Aquila et al., 1994; Hirano et al., 2007) . It should be emphasized that all the results presented here cannot be attributed to a locomotor effect, since the administration of ursolic acid alone or in combination with all the dopaminergic agents did not significantly affect the ambulatory or exploratory behavior of mice in the open-field test. Moreover, no signals of stereotypy were observed in mice treated with ursolic acid separately or in association with pharmacological agents. Although not significant, the decrease in locomotion caused by combination of SCH23390 with ursolic acid might explain the fact that SCH23390 reversed the decrease on immobility time caused by ursolic acid in the TST. However, this hypothesis is not probable considering that sub-effective doses of ursolic acid and the dopamine D1 receptor agonist SKF38393 caused an anti-immobility effect in the TST, without causing a psychostimulant effect in the open-field test, suggesting that dopamine D1 receptors are implicated in the antidepressant-like effect of ursolic acid in the TST.
The importance of our results are highlighted by the fact that dopamine receptor agonists have been thought as one of the promising candidates to improve outcomes of patients with treatment-resistant and non remitting depression (Dunlop and Nemeroff, 2007; Rakofsky et al., 2009) . Moreover, here we show that the antidepressant-like effect elicited by ursolic acid (0.1 mg/kg, p.o) in the TST is similar to the effect produced by bupropion administered at a dose 100 fold higher (10 mg/kg, p.o.). Bupropion is a useful antidepressant for the treatment of SSRI or selective noradrenaline reuptake inhibitor-resistant depression (Baumann, 2007) . Therefore, it remains to be established if ursolic acid alone or in combination with bupropion is effective in animals models of depression associated with anhedonia, a core symptom of depression.
Although there is no report regarding the side-effects of ursolic acid in humans, hepatoprotective and neuroprotective activities as beneficial properties of this compound were reported (Ikeda et al., 2008) . Moreover, considering that several antidepressants show adverse side effects, which include sexual dysfunction, insomnia, gastrointestinal disorders, hypotension (Berton and Nestler, 2006) , the use of ursolic acid in association with antidepressants such as bupropion could enhance their therapeutic response and decrease their side-effects by allowing lower doses to be prescribed. Furthermore, ursolic acid displays a promising therapeutic advantage since it produced an antidepressant-like effect similar to classical antidepressants but at lower doses and was also reported to cause non-toxic effects (Liu, 1995) , suggesting its therapeutic applicability that needs to be investigated in future studies.
Conclusion
The present work demonstrates that ursolic acid is effective in producing an antidepressant-like effect in the TST and FST when administered by p.o. route. Moreover, a clear involvement of the dopaminergic system in its antidepressant-like effect was indicated by the reversal of its effect by the pretreatment of mice with dopamine D 1 and D 2 receptor antagonists and also, by the synergistic antidepressant-like effect afforded by the dopamine D 1 and D 2 receptor agonists, as well as the antidepressant bupropion. Altogether, the results suggest that an activation of dopamine D 1 and D 2 receptors is implicated in the antidepressant-like effect of ursolic acid in the TST. Overall, the results reported in the present study indicate the antidepressant potential of ursolic acid in a preclinical test widely recognized as effective to assess antidepressant activity, suggesting that it should be further investigated as a possible agent for the treatment of depression.
